David H Ilson Selected Research

David H Ilson Research Topics

Disease

69	Neoplasms (Cancer) 02/2024 - 05/2002
51	Adenocarcinoma 02/2024 - 09/2006
38	Esophageal Neoplasms (Esophageal Cancer) 11/2023 - 04/2002
32	Stomach Neoplasms (Stomach Cancer) 02/2024 - 05/2002
13	Pathologic Complete Response 02/2024 - 09/2003
8	Microsatellite Instability 02/2024 - 01/2018
8	Neoplasm Metastasis (Metastasis) 10/2019 - 05/2002
7	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023 - 05/2002
7	Disease Progression 11/2020 - 11/2006
6	Neutropenia 01/2020 - 01/2004
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2023 - 04/2011
4	Carcinoma (Carcinomatosis) 01/2020 - 08/2002
3	Leukemia 01/2023 - 12/2004
3	Hypertension (High Blood Pressure) 01/2019 - 11/2006
3	Colonic Neoplasms (Colon Cancer) 11/2018 - 04/2014
3	Deglutition Disorders (Dysphagia) 08/2003 - 05/2002
2	Margins of Excision 11/2023 - 11/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 05/2017
2	Sudden Death 01/2022 - 01/2019
2	Fistula 01/2022 - 03/2009
2	Heart Arrest (Cardiac Arrest) 01/2019 - 11/2018
2	Esophageal Squamous Cell Carcinoma 01/2019 - 03/2009
2	Colorectal Neoplasms (Colorectal Cancer) 11/2018 - 05/2007
2	Breast Neoplasms (Breast Cancer) 09/2014 - 01/2003
2	Stomatitis 01/2004 - 08/2003
2	Diarrhea 01/2004 - 08/2003
2	Esophagitis 01/2004 - 08/2003
2	Lung Neoplasms (Lung Cancer) 01/2003 - 05/2002
1	Residual Neoplasm 11/2023
1	Atherosclerosis 01/2023
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2022
1	Lymphadenopathy 01/2022
1	Infections 01/2022
1	Anastomotic Leak 01/2022
1	Sepsis (Septicemia) 01/2022
1	Obesity 11/2021

Drug/Important Bio-Agent (IBA)

24	Cisplatin (Platino)FDA LinkGeneric 11/2019 - 04/2002
15	Irinotecan (Camptosar)FDA LinkGeneric 12/2016 - 05/2002
14	Trastuzumab (Herceptin)FDA Link 11/2023 - 05/2013
12	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 04/2002
11	Immune Checkpoint InhibitorsIBA 02/2024 - 11/2016
10	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2017
10	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2003
9	pembrolizumabIBA 02/2024 - 11/2018
8	NivolumabIBA 02/2024 - 11/2017
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2007
6	trifluridine tipiracil drug combinationIBA 01/2022 - 11/2018
6	Docetaxel (Taxotere)FDA Link 11/2019 - 09/2006
6	Epirubicin (Ellence)FDA LinkGeneric 11/2017 - 04/2002
6	Bevacizumab (Avastin)FDA Link 11/2017 - 11/2006
5	LigandsIBA 02/2024 - 11/2017
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2021 - 09/2006
4	RamucirumabIBA 01/2022 - 02/2015
4	Leucovorin (Folinic Acid)FDA Link 01/2020 - 03/2011
3	Monoclonal AntibodiesIBA 10/2023 - 09/2011
3	ErbB Receptors (EGF Receptor)IBA 10/2021 - 01/2007
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 01/2015
3	Tyrosine Kinase InhibitorsIBA 01/2015 - 04/2011
3	Growth Factor ReceptorsIBA 02/2004 - 05/2002
2	ClaudinsIBA 11/2023 - 10/2023
2	zolbetuximabIBA 11/2023 - 10/2023
2	regorafenibIBA 10/2023 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2019
2	B7-H1 AntigenIBA 01/2023 - 01/2022
2	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 09/2006
2	Epidermal Growth Factor (EGF)IBA 11/2017 - 04/2014
2	Capecitabine (Xeloda)FDA Link 11/2017 - 08/2016
2	Cetuximab (Erbitux)FDA Link 10/2016 - 04/2014
1	Programmed Cell Death 1 ReceptorIBA 02/2024
1	IpilimumabIBA 11/2023
1	Immunoglobulin G (IgG)IBA 10/2023
1	Complement System Proteins (Complement)IBA 10/2023
1	Trinitrotoluene (TNT)IBA 06/2023
1	Circulating Tumor DNAIBA 01/2023
1	durvalumabIBA 01/2023
1	Small Cytoplasmic RNAIBA 01/2023
1	zirconium-89-trastuzumabIBA 01/2023
1	crenolanibIBA 01/2022
1	bemarituzumabIBA 11/2021
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 11/2021
1	pyrimidineIBA 11/2021
1	Death Domain ReceptorsIBA 11/2021
1	Protons (Proton)IBA 11/2020
1	trastuzumab deruxtecanIBA 11/2020
1	avelumabIBA 11/2020
1	ElectrolytesIBA 01/2020

Therapy/Procedure

59	Therapeutics 02/2024 - 05/2002
58	Drug Therapy (Chemotherapy) 02/2024 - 05/2002
24	Chemoradiotherapy 02/2024 - 05/2002
22	Radiotherapy 01/2023 - 05/2002
11	Combined Modality Therapy 01/2021 - 08/2002
10	Neoadjuvant Therapy 06/2023 - 03/2008
9	Induction Chemotherapy 01/2023 - 05/2002
8	Adjuvant Chemotherapy 01/2024 - 11/2016
7	Esophagectomy 11/2023 - 09/2005
7	Gastrectomy 11/2023 - 05/2013
3	Immunotherapy 10/2021 - 01/2018
3	Adjuvant Chemoradiotherapy 07/2009 - 12/2008
1	Adjuvant Radiotherapy 11/2021
1	Proton Therapy 11/2020